Fetal Aneuploidy Confirmation Testing Global Market Report 2026

The fetal aneuploidy confirmation testing market size has grown rapidly in recent years. It will grow from $1.43 billion in 2025 to $1.58 billion in 2026 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to rising maternal age pregnancies, increasing prevalence of chromosomal abnormalities, growing awareness of prenatal screening programs, advancements in cytogenetic testing methods, expansion of hospital-based diagnostic laboratories.

The fetal aneuploidy confirmation testing market size is expected to see rapid growth in the next few years. It will grow to $2.36 billion in 2030 at a compound annual growth rate (CAGR) of 10.6%. The growth in the forecast period can be attributed to increasing adoption of precision medicine approaches, growing integration of ai-based genetic analysis tools, rising demand for non-invasive prenatal testing confirmation, expansion of genomic research initiatives, increasing healthcare infrastructure investments in emerging markets. Major trends in the forecast period include increasing adoption of next-generation sequencing technologies, rising demand for early and accurate prenatal diagnosis, growing preference for confirmatory diagnostic testing after positive screening, expansion of advanced chromosomal microarray analysis, increasing availability of specialized prenatal diagnostic services.

The rising maternal age is anticipated to drive the growth of the fetal aneuploidy confirmation testing market in the coming years. Maternal age refers to the age of a woman when she becomes pregnant or delivers a child. The increase in maternal age is attributed to women postponing childbirth to pursue higher education and prioritize career development before starting a family. Fetal aneuploidy confirmation testing mitigates the risks linked to increasing maternal age by accurately detecting chromosomal abnormalities that are more prevalent in pregnancies among older women, enabling timely medical guidance and well-informed pregnancy decisions. For example, in June 2025, according to the Centers for Disease Control and Prevention, a US-based government agency, the average age of mothers at first birth rose from 27.4 years in 2022 to 27.5 years in 2023, representing an increase of 0.1 years. Therefore, the rise in maternal age is fueling the growth of the fetal aneuploidy confirmation testing market.

The expansion of personalized medicine is expected to drive the growth of the fetal aneuploidy confirmation testing market in the coming years. Personalized medicine is a healthcare approach that customizes prevention, diagnosis, and treatment strategies according to an individual's unique genetic profile, biomarkers, and molecular characteristics. The adoption of personalized medicine is rising due to rapid advancements in genomic technologies and biomarker-based diagnostics, which allow clinicians to tailor treatments and interventions to an individual’s genetic makeup. Fetal aneuploidy confirmation testing supports personalized medicine by providing accurate genetic information about the fetus, enabling healthcare providers to customize prenatal care, risk management, and treatment decisions specifically to the genetic profile of each pregnancy. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized therapies for patients with rare diseases, reflecting a significant increase from the six approvals recorded in 2022. Therefore, the growth of personalized medicine is driving the expansion of the fetal aneuploidy confirmation testing market.

The increasing prevalence of chromosomal abnormalities is expected to propel the growth of the fetal aneuploidy confirmation testing market in the coming years. Chromosomal abnormalities are genetic disorders resulting from changes in chromosome number or structure, leading to conditions such as trisomies and other aneuploidies. The prevalence of these abnormalities is rising due to increasing maternal age, as older maternal age is linked to a higher risk of errors during cell division that result in conditions like trisomies and other aneuploidies. Fetal aneuploidy confirmation testing facilitates the detection and confirmation of chromosomal abnormalities in the developing fetus by analyzing genetic material, allowing early diagnosis, informed clinical decisions, and timely management of conditions such as trisomies and other aneuploidies. For example, in November 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, approximately 5,700 babies are born with Down syndrome in the United States each year, corresponding to roughly 1 in every 640 births. Therefore, the increasing prevalence of chromosomal abnormalities is driving the growth of the fetal aneuploidy confirmation testing market.

Major companies operating in the fetal aneuploidy confirmation testing market are Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Illumina Inc., PerkinElmer Inc., SYNLAB AG, Myriad Genetics Inc., CapitalBio Technology Co. Ltd., BGI Genomics Co. Ltd., Centogene N.V., Yourgene Health plc, MedGenome Labs Ltd., Fulgent Genetics Inc., Annoroad Gene Technology Co. Ltd., CeGaT GmbH, LifeCodexx AG, Variantyx Inc., Igenomix S.L.U.

North America was the largest region in the fetal aneuploidy confirmation testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fetal aneuploidy confirmation testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the fetal aneuploidy confirmation testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fetal aneuploidy confirmation testing market consists of revenues earned by entities by providing services such as genetic counseling, diagnostic sampling procedures including amniocentesis and chorionic villus sampling, laboratory-based cytogenetic analysis, and rapid aneuploidy detection. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fetal aneuploidy confirmation testing refers to diagnostic procedures that verify chromosomal abnormalities in a fetus following an initial screening indicating elevated risk. These tests often involve invasive techniques such as amniocentesis or chorionic villus sampling to directly examine fetal chromosomes. They provide definitive information about conditions like trisomy 21, trisomy 18, and trisomy 13 by evaluating chromosome number and structure.

The primary test types of fetal aneuploidy confirmation testing include non-invasive prenatal testing, invasive testing, and other variants. Non-invasive prenatal testing analyzes cell-free fetal DNA from maternal blood to detect chromosomal abnormalities. Technologies include next-generation sequencing, polymerase chain reaction, fluorescence in situ hybridization, microarray, and others. Applications include trisomy, sex chromosome aneuploidy, microdeletions, and others, serving hospitals, diagnostic laboratories, specialty clinics, and other end-users.

Tariffs on imported sequencing platforms, microarray equipment, reagents, and laboratory consumables have influenced the fetal aneuploidy confirmation testing market by raising operational costs for diagnostic laboratories and hospitals. Regions such as North America and Europe that depend on advanced genetic testing instruments from global suppliers face increased procurement expenses, particularly affecting next-generation sequencing and microarray segments. Smaller specialty clinics may experience slower technology adoption due to higher capital costs. However, tariffs are also encouraging domestic production of genetic testing reagents and laboratory technologies, fostering local innovation and strengthening regional genomic testing capabilities.

The fetal aneuploidy confirmation testing market research report is one of a series of new reports that provides fetal aneuploidy confirmation testing market statistics, including fetal aneuploidy confirmation testing industry global market size, regional shares, competitors with a fetal aneuploidy confirmation testing market share, detailed fetal aneuploidy confirmation testing market segments, market trends and opportunities, and any further data you may need to thrive in the fetal aneuploidy confirmation testing industry. This fetal aneuploidy confirmation testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.